Bagsværd, Denmark, 3 December 2016 - Novo Nordisk today announced that NovoSeven® (rFVIIa), a portable room temperature stable recombinant activated factor VIIa, resolved 96.5% of bleeds when initiated within one hour after onset of bleeding, demonstrating efficacy of early treatment in people with haemophilia A or B with inhibitors.1 Efficacy also remained high for bleeds treated after 4 hours.1 A subanalysis of the SMART-7(TM) study, evaluating the efficacy of NovoSeven® in a real-world setting, was presented today at the 58th American Society of Haematology (ASH) annual meeting.
Further information
Media: | ||
Katrine Sperling | +45 4442 6718 | krsp@novonordisk.com |
Åsa Josefsson | +45 3079 7708 | aajf@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com |
Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
Hannah Ögren | +45 3075 8519 | haoe@novonordisk.com |
Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
References
- Benson, G. et al. Benefit of early treatment with Room Temperature Stable Recombinant Activated Factor VII (rFVIIa) in patients with Hemophilia A or B with inhibitors: Subgroup Analysis from the Prospective, Post-Authorization, Non-interventional SMART-7(TM) Study. Poster number 1439. 58th American Society of Haematology (ASH) annual meeting. 3 December 2016.